Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline Review, H2 2017’, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

The report reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics and enlists all their major and minor projects

The report assesses Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Antibiotx ApS

ContraFect Corp

Debiopharm International SA

Destiny Pharma Ltd

Sealife PHARMA GMBH

Tetraphase Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview 6

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development 20

Antibiotx ApS 20

ContraFect Corp 20

Debiopharm International SA 20

Destiny Pharma Ltd 21

Sealife PHARMA GMBH 21

Tetraphase Pharmaceuticals Inc 22

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles 23

afabicin - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

CF-301 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

exeporfinium chloride - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

NAI-108 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

niclosamide - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

SLP-0904 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

SLP-0905 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules for Bacterial Infections - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

targocil - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

TP-271 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects 44

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products 45

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones 46

Featured News & Press Releases 46

Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 17

Number of Products by Stage and Molecule Type, H2 2017 19

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by Antibiotx ApS, H2 2017 20

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by ContraFect Corp, H2 2017 20

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by Debiopharm International SA, H2 2017 21

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by Destiny Pharma Ltd, H2 2017 21

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by Sealife PHARMA GMBH, H2 2017 22

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 22

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Dormant Projects, H2 2017 44

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Discontinued Products, H2 2017 45

List of Figures

List of Figures

Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Number of Products by Targets, H2 2017 12

Number of Products by Stage and Targets, H2 2017 12

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 16

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 18

Number of Products by Stage and Molecule Types, H2 2017 18

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports